Is IL-6 the Right Target in COVID-19 Severe Pneumonia?

Blot, Mathieu; Bourredjem, Abderrahmane; Binquet, Christine; Piroth, Lionel

Blot, Mathieu; Bourredjem, Abderrahmane; Binquet, Christine; Piroth, Lionel.

Blot M; Infectious Diseases Department University Hospital Dijon, France.
Bourredjem A; LNC INSERM UMR1231 Dijon, France and.
Binquet C; INSERM CIC1432 Clinical Epidemiology unit Dijon, France.
Piroth L; LNC INSERM UMR1231 Dijon, France and.

Am J Respir Crit Care Med ; 203(1): 139-140, 2021 01 01.

Article in English | MEDLINE | ID: covidwho-1058973

Subject(s)

COVID-19; Interleukin-6; Antibodies, Monoclonal, Humanized; Humans; SARS-CoV-2; Severity of Illness Index

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Am J Respir Crit Care Med Journal subject: Critical Care Year: 2021 Document Type: Article Affiliation country: Rccm.202007-2924LE

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google